BF Biosciences Limited (PSX:BFBIO)
Pakistan · Delayed Price · Currency is PKR 139.13
+1.08 (0.78%)
At close: Jun 2, 2026
BF Biosciences Cash Flow Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Income | 591.76 | 447.15 | 385.41 | 149.05 | 306.98 | 607.99 |
Depreciation & Amortization | 268.83 | 191.92 | 35.57 | 33.78 | 28 | 23 |
Other Amortization | 1.85 | 1.69 | 0.55 | 0.55 | - | - |
Loss (Gain) From Sale of Assets | -4.36 | -2.79 | -2.13 | -1.06 | - | - |
Loss (Gain) From Sale of Investments | -40.17 | -27.3 | -0.21 | -8.93 | - | - |
Other Operating Activities | 166.68 | 44.33 | 305.49 | 32.12 | -156.98 | -60.99 |
Change in Accounts Receivable | -269.06 | 20.37 | -110.82 | -41.1 | - | - |
Change in Inventory | -889.76 | -846.4 | -41.57 | -445.69 | - | - |
Change in Accounts Payable | 461.84 | 472.43 | 196.75 | -5.94 | - | - |
Change in Unearned Revenue | -2.62 | -5.27 | 19.75 | -17.78 | - | - |
Change in Other Net Operating Assets | -14.94 | 3.66 | -124.09 | 108.94 | - | - |
Operating Cash Flow | 297.3 | 299.79 | 664.7 | -196.07 | 178 | 570 |
Operating Cash Flow Growth | - | -54.90% | - | - | -68.77% | - |
Capital Expenditures | -513.91 | -329.49 | -143.13 | -1,968 | -1,130 | -941 |
Sale of Property, Plant & Equipment | 8.25 | 3.86 | 4.4 | 1.06 | - | - |
Sale (Purchase) of Intangibles | 5.12 | - | - | -1.66 | - | - |
Investment in Securities | 551.05 | -1,100 | 108.58 | 1,161 | - | - |
Other Investing Activities | 13.14 | 91 | 16.34 | 83.4 | -333 | -399 |
Investing Cash Flow | 63.66 | -1,335 | -13.81 | -724.44 | -1,463 | -1,340 |
Long-Term Debt Issued | - | 93.55 | - | 811.02 | - | - |
Long-Term Debt Repaid | - | -436.19 | -321.36 | -50.5 | - | - |
Net Debt Issued (Repaid) | -483.8 | -342.64 | -321.36 | 760.52 | - | - |
Issuance of Common Stock | - | 1,855 | - | - | - | - |
Other Financing Activities | -73.56 | -112.25 | -161.52 | -120.28 | 925 | 1,162 |
Financing Cash Flow | -557.36 | 1,400 | -482.88 | 640.24 | 925 | 1,162 |
Miscellaneous Cash Flow Adjustments | - | - | - | - | 1 | 1 |
Net Cash Flow | -196.4 | 365.04 | 168.02 | -280.27 | -359 | 393 |
Free Cash Flow | -216.61 | -29.71 | 521.57 | -2,164 | -952 | -371 |
Free Cash Flow Margin | -2.44% | -0.51% | 14.26% | -119.61% | -62.60% | -21.14% |
Free Cash Flow Per Share | -2.45 | -0.37 | 8.23 | -34.17 | -15.03 | -5.86 |
Cash Interest Paid | 73.56 | 112.25 | 161.52 | 120.28 | - | - |
Cash Income Tax Paid | 302.1 | 279.05 | 51.39 | 73.4 | - | - |
Levered Free Cash Flow | -437.43 | -255.5 | 313.25 | -2,306 | -834 | -670.45 |
Unlevered Free Cash Flow | -393.53 | -183.39 | 401.52 | -2,306 | -792.99 | -654.66 |
Change in Working Capital | -714.55 | -355.21 | -59.98 | -401.58 | - | - |